Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

ASX Announcements

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Sep 21, 2022
Cleansing notice
Sep 16, 2022
Application for quotation of securities - KZA
Sep 16, 2022
Cleansing notice
Sep 14, 2022
Kazia presentation to HCW Bioconnect
Sep 8, 2022
Ceasing to be a substantial holder
Sep 8, 2022
Change in Directors interests
Sep 8, 2022
Kazia to present at ESMO
Aug 29, 2022
Kazia Corporate Governance Statement
Aug 29, 2022
Kazia Appendix 4G
Aug 29, 2022
Kazia Appendix 4E
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • …
  • Page 19
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement